BioSpace News Archive

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2020 financial and operating results on Thursday, November 5, 2020 , before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM Eastern Time that day. Conference Cal

Third cohort added to independently evaluate the efficacy of NantKwest’s PD-L1 t-haNK natural killer cells plus ImmunityBio’s IL-15 superagonist Anktiva™ (N-803) in third-line or greater therapy for patients with locally advanced or metastatic pancreatic cancer. Two other cohorts for first-line maintenance and second-line randomized against standards of care chemotherapy. 40 patients are currently enrolled in or being evaluated for the Phase 2

Silicon Therapeutics , a privately-held, fully integrated drug design, discovery and development company focused on small molecule therapeutics, today introduced an updated corporate website, which reflects the company’s mission, research approach and core values. The new Silicon Therapeutics site more accurately tells the company’s story and clearly highlights the company’s mission to improve the lives of patients by creati

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody ® technology platform, today announced the planned retirement from CytomX of W. Michael Kavanaug

Haemonetics Corporation (NYSE:HAE) announced that the Company intends to publish second quarter fiscal year 2021 financial results at 6:00 am EDT on Wednesday, November 4, 2020 . The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EDT on November 4 , 2020.

- Third Quarter Product and Service Revenue of $30.1 Million vs. Guidance Range of $25 to $28 Million - - More than 25 New GeoMx DSP Orders Received in the Third Quarter - SEATTLE--( BUSINESS WIRE )-- NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today provided preliminary financial and operational highlights for the third quarter of 2020. Financial Highlig

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that it has commenced an underwritten public offering of $150,000,000 of shares of its common stock. All of the shares in the offering will be sold by SpringWorks. In addition, SpringWorks expects to grant the underwriters a 30-day option to pu

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Fourth Quarter Fiscal 2020 on Thursday, November 5, 2020, prior to the opening of trading on the New York Stock Exchange

Guardant Health, Inc. (Nasdaq: GH) (“Guardant Health”), a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics, announced today the commencement of a proposed underwritten public offering of 7,000,000 shares of its common stock being offered for sale by SoftBank Investment Advisers

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that it intends to offer and sell, subject to market and other conditions, $150.0 million of shares of its common stock in an underwritten public offering pursuant to NanoString’s shelf registration statement. In connection with this offering, NanoString expects to grant the underwriters